Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...
Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.
Switching to tirzepatide associated with hemoglobin A1c reduction and weight loss compared with escalating treatment with dulaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback